We are live on
!
Find out more
IHM
Iguana Healthcare Management Portfolio holdings
AUM
$152M
1-Year Est. Return
48.74%
This Fund
S&P 500
This Quarter
Est. Return
+10.75%
1 Year Est. Return
+48.74%
3 Year Est. Return
+142.13%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$317M
AUM Growth
+$79.3M
(+33%)
Cap. Flow
+$66.9M
Cap. Flow
% of AUM
21.11%
Top 10 Holdings %
Top 10 Hldgs %
43.22%
Holding
98
New
36
Increased
16
Reduced
11
Closed
29
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Amgen
AMGN
|
+$9.61M |
| 2 |
Bausch Health
BHC
|
+$7.76M |
| 3 |
Medtronic
MDT
|
+$7.64M |
| 4 |
Biogen
BIIB
|
+$6.02M |
| 5 |
Viatris
VTRS
|
+$5.3M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Pfizer
PFE
|
+$13.7M |
| 2 |
AGN
Allergan plc
AGN
|
+$7.44M |
| 3 |
iShares Russell 2000 ETF
IWM
|
+$6.22M |
| 4 |
Puma Biotechnology
PBYI
|
+$5.9M |
| 5 |
Zimmer Biomet
ZBH
|
+$5.88M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 67.88% |
| 2 | Technology | 0.31% |
| 3 | Real Estate | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1
PUT
State Street SPDR S&P 500 ETF Trust
SPY
$806B
| $20.6M | 6.49% |
+100,000
| New | +$21M |
|
2
Ultragenyx Pharmaceutical
RARE
$2.47B
| $20.5M | 6.46% |
200,000
+25,000
| +14% | +$1.94M |
|
|
CELG
3
DELISTED
Celgene Corp
CELG
| $17.4M | 5.48% |
150,000
+40,000
| +36% | +$4.57M |
|
4
PUT
State Street Health Care Select Sector SPDR ETF
XLV
$41.8B
| $14.9M | 4.69% |
+200,000
| New | +$14.8M |
|
|
5
CALL
Pfizer
PFE
$142B
| $13.4M | 4.23% |
+421,600
| New | +$13.7M |
|
|
ESPR
6
DELISTED
Esperion Therapeutics
ESPR
| $12.3M | 3.87% |
150,000
-50,000
| -25% | -$4.89M |
|
7
Gilead Sciences
GILD
$161B
| $11.7M | 3.69% |
100,000
| – | – |
|
|
8
Amgen
AMGN
$204B
| $9.21M | 2.91% |
+60,000
| New | +$9.61M |
|
|
ESRX
9
DELISTED
Express Scripts Holding Company
ESRX
| $8.89M | 2.81% |
100,000
+40,000
| +67% | +$3.49M |
|
10
Elevance Health
ELV
$82.4B
| $8.21M | 2.59% |
50,000
+30,000
| +150% | +$4.79M |
|
|
11
Bausch Health
BHC
$2.6B
| $7.78M | 2.45% |
+35,000
| New | +$7.76M |
|
|
12
Medtronic
MDT
$110B
| $7.41M | 2.34% |
+100,000
| New | +$7.64M |
|
|
STJ
13
DELISTED
St Jude Medical
STJ
| $7.31M | 2.31% |
100,000
+25,000
| +33% | +$1.81M |
|
|
AXDX
14
DELISTED
Accelerate Diagnostics
AXDX
| $6.97M | 2.2% |
27,000
+2,000
| +8% | +$478K |
|
|
HZNP
15
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
| $6.95M | 2.19% |
200,000
| – | – |
|
|
16
Pfizer
PFE
$142B
| $6.71M | 2.12% |
210,800
-421,600
| -67% | -$13.7M |
|
17
Cigna
CI
$74.8B
| $6.48M | 2.04% |
40,000
+10,000
| +33% | +$1.38M |
|
|
AET
18
CALL
DELISTED
Aetna Inc
AET
| $6.37M | 2.01% |
+50,000
| New | +$5.71M |
|
|
19
Biogen
BIIB
$29.7B
| $6.06M | 1.91% |
+15,000
| New | +$6.02M |
|
|
IPXL
20
DELISTED
Impax Laboratories, Inc.
IPXL
| $5.74M | 1.81% |
125,000
+50,000
| +67% | +$2.37M |
|
|
GWPH
21
DELISTED
GW Pharmaceuticals Plc American Depositary Shares
GWPH
| $5.53M | 1.74% |
45,000
-5,000
| -10% | -$567K |
|
|
22
Viatris
VTRS
$20.4B
| $5.09M | 1.61% |
+75,000
| New | +$5.3M |
|
23
Edwards Lifesciences
EW
$51.1B
| $4.99M | 1.57% |
+210,000
| New | +$4.74M |
|
24
CALL
Abbott
ABT
$185B
| $4.91M | 1.55% |
+100,000
| New | +$4.8M |
|
|
NVDQ
25
DELISTED
Novadaq Technologies Inc.
NVDQ
| $4.84M | 1.53% |
400,000
+200,000
| +100% | +$2.39M |
|
Similar funds
HWP
PAM
USG2
LCM
FPF
FIAS
CII
OPWM
Iguana Healthcare Management's Q2 2015 Portfolio in Review
As of Q2 2015, Iguana Healthcare Management held 98 positions worth $317M, up 33% from $238M the previous quarter. Its ten largest holdings account for 43% of the portfolio.
Iguana Healthcare Management deployed $66.9M of net new capital in Q2 2015, opening 36 new positions and adding to 16 existing holdings. Its largest new stake was Amgen: 60,000 shares worth $9.21M.
By sector, the portfolio is most concentrated in Healthcare at 68% of assets, down from 82% a quarter earlier, followed by Technology and Real Estate.
On the sell side, the largest reduction was Pfizer, an estimated $13.7M trimmed.
- Iguana Healthcare Management's largest Q2 2015 buy was Amgen: 60,000 shares worth $9.21M.
- Iguana Healthcare Management added most to Elevance Health in Q2 2015, an estimated $4.79M increase.
- Iguana Healthcare Management's biggest Q2 2015 reduction was Pfizer, cutting an estimated $13.7M.
- Iguana Healthcare Management fully exited Allergan plc in Q2 2015, selling an estimated $7.44M.
- Iguana Healthcare Management's ten largest holdings make up 43% of its $317M portfolio in Q2 2015.
- Iguana Healthcare Management opened 36 new positions and closed 29 in Q2 2015.
- Iguana Healthcare Management's portfolio value rose 33% quarter-over-quarter to $317M.
Based on Iguana Healthcare Management's 13F filing for Q2 2015, filed 14 Aug 2015.